Consistent with previous reports that combine Notch inhibition with anti-leukemic drugs in myeloma,33 B-ALL34,35, and CLL,36 our research supports the idea of dual inhibition of FLT3 and NOTCH signaling with small molecules as a potential strategy for FLT3/ITD + AML treatment. The gene discussed is FLT3; the disease is plasma cell myeloma.